ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1400 participants.

Also called NCT02910089

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 1,400 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02910089
Other papers using this trial's data
  • Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: The ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial PloS one, 2019 DOI, PubMed 30939143, PMC6445420 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02910089. Randomized; no masking; primary purpose other. Start 2016-10-20 (actual); primary completion 2017-12-20 (actual). Results posted on 2019-08-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
Acronym
ENGAGE-DM
Condition
Diabetes Mellitus Type 2
Intervention (Behavioral)
Shared Decision Making
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Brigham Women's Health (class: not stated)

Record details

Record id
cardio:ct-nct02910089
Content hash
4ef614a84d03ba8ca62abd70ff9f825e3c1ef5277799b92ab46ea2b4a83630bd